Valuation: Isofol Medical AB

Market Cap 260M 26.92M 23.53M 21.62M 20.16M 38.23M 2.56B 38.81M 101M 1.26B 101M 98.86M 4.34B P/E 2026 *
-4.26x
P/E 2027 * -27x
Enterprise Value 158M 16.34M 14.28M 13.13M 12.24M 23.21M 1.56B 23.56M 61.27M 765M 61.33M 60.02M 2.64B EV / Sales 2026 *
-
EV / Sales 2027 * 3.89x
Free-Float
90.89%
Yield 2026 *
-
Yield 2027 * -
1 day+5.88%
1 week+14.57%
Current month+10.05%
1 month+10.96%
3 months+20.36%
6 months+8.58%
Current year+11.11%
1 week 0.71
Extreme 0.707
0.84
1 month 0.68
Extreme 0.675
0.84
Current year 0.55
Extreme 0.5515
0.99
1 year 0.55
Extreme 0.5515
1.18
3 years 0.45
Extreme 0.45
4.88
5 years 0.45
Extreme 0.45
14.44
10 years 0.45
Extreme 0.45
33.5
Manager TitleAgeSince
Chief Executive Officer 74 2024-01-08
Director of Finance/CFO 60 2024-08-12
Chief Executive Officer 61 2023-06-21
Director TitleAgeSince
Chairman 85 2010-06-30
Chairman 81 2011-12-31
Director/Board Member 78 2024-01-03
Date Insider Type Main position Quantity % Market Cap.
21-12-09Sell 58,767 0.0364%
21-12-09Sell 58,767 0.0364%
21-06-13
Healthcom GmbH
BuyCompany 233,336 0.2239%
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+14.57%-5.15%+54.88% 26.92M
+3.34%+0.70%+60.09%+13.32% 320B
-1.25%0.00%+31.51%-2.02% 72.44B
+3.17%+5.99%+47.13%+115.43% 9.42B
+1.24%+4.51%+6.84%-0.78% 8.65B
-0.46%+3.98%-8.00%+4.61% 4.41B
+8.48%+25.95%+23.98%+52.99% 4.52B
+0.43%+6.02%-36.00%+22.59% 3.43B
+1.35%+2.58%+50.25%+60.70% 2.79B
-1.28%+7.61%+15.42%-23.44% 2.19B
Average +2.09%+4.25%+18.61%+29.83% 42.79B
Weighted average by Cap. +2.47%+2.85%+51.74%+13.22%

Financials

2026 *2027 *
Net sales - 43.33M 4.49M 3.93M 3.61M 3.36M 6.38M 428M 6.48M 16.85M 210M 16.86M 16.5M 725M
Net income -61.25M -6.35M -5.55M -5.1M -4.76M -9.02M -605M -9.16M -23.81M -297M -23.84M -23.33M -1.02B -40.15M -4.16M -3.64M -3.34M -3.12M -5.91M -396M -6M -15.61M -195M -15.63M -15.29M -671M
Net Debt -102M -10.58M -9.25M -8.5M -7.92M -15.02M -1.01B -15.25M -39.65M -495M -39.7M -38.84M -1.71B -91M -9.44M -8.25M -7.58M -7.07M -13.4M -898M -13.6M -35.38M -442M -35.42M -34.66M -1.52B
Logo Isofol Medical AB
Isofol Medical AB is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Employees
6
Date Price Change Volume
26-07-03 SEK 0.8100 +5.88% 1,394,039
26-07-02 SEK 0.7650 +1.32% 679,514
26-07-01 SEK 0.7550 +2.58% 96,649
26-06-30 SEK 0.7360 +1.94% 148,394
26-06-29 SEK 0.7220 +2.12% 336,943
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISOFOL Stock